โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ’Š

Stivarga

regorafenib
Colorectal Neoplasms
โœ… Authorised
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Stivarga is indicated as monotherapy for the treatment of adult patients with: metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy; unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib; hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

โš ๏ธ Patient safety

No

โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.